Overview

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Status:
Suspended

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Priyanka Sharma

Collaborators:

Bristol-Myers Squibb
Celgene Corporation

Treatments:

Cisplatin
Histone Deacetylase Inhibitors
Nivolumab
Romidepsin